GoAI
Get started
Delta-Fly Pharma, Inc. logo

Delta-Fly Pharma, Inc.

4598.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥106

−¥3.00 · -2.75%

Aug 24, 3:30 PM JST

4598.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Kiyoshi Eshima
Listed since
Oct 12, 2018
Employees
12

Market position

52-week range

Current ¥106

Open
¥106
Previous close
¥109
Volume
0
0× average
Average volume
237.37K
Average daily volume
Market cap
1.51B JPY
Beta
-0.72
Market reference 1
50-day average
¥118.56
-10.59% below average
200-day average
¥257.54
-58.84% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.78×
P/B (TTM)
-7.56×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0×

Financial statements

Income trends

Operating income

−1.61B JPY+6.04%

Net income

−1.63B JPY+5.53%
Income trends across reported periods−885.49M JPY−1.19B JPY−1.49B JPY−1.8B JPYOperating income, FY2022: −961.46M JPYOperating income, FY2023: −1.32B JPYOperating income, FY2024: −1.4B JPYOperating income, FY2025: −1.71B JPYOperating income, FY2026: −1.61B JPYNet income, FY2022: −967.3M JPYNet income, FY2023: −1.33B JPYNet income, FY2024: −1.43B JPYNet income, FY2025: −1.72B JPYNet income, FY2026: −1.63B JPYFY2022FY2023FY2024FY2025FY2026
Operating income FY2022 −961.46M JPY. Operating income FY2023 −1.32B JPY. Operating income FY2024 −1.4B JPY. Operating income FY2025 −1.71B JPY. Operating income FY2026 −1.61B JPY. Net income FY2022 −967.3M JPY. Net income FY2023 −1.33B JPY. Net income FY2024 −1.43B JPY. Net income FY2025 −1.72B JPY. Net income FY2026 −1.63B JPY.
Metric (JPY)FY2026FY2025FY2024FY2023FY2022
Revenue————300M JPY
Cost of goods sold1.44M JPY1.59M JPY1.51M JPY1.63M JPY—
Gross profit−1.44M JPY−1.59M JPY−1.51M JPY−1.63M JPY300M JPY
Research and development1.33B JPY1.44B JPY1.12B JPY1.01B JPY940.79M JPY
Selling, general, and administrative273.97M JPY209.6M JPY227.07M JPY258.98M JPY284.97M JPY
Operating expenses1.6B JPY1.71B JPY1.4B JPY1.31B JPY1.26B JPY
Interest income921K JPY337K JPY14K JPY13K JPY70K JPY
Depreciation and amortization1.44M JPY1.59M JPY1.51M JPY1.63M JPY1.67M JPY
Operating income−1.61B JPY−1.71B JPY−1.4B JPY−1.32B JPY−961.46M JPY
Net income−1.63B JPY−1.72B JPY−1.43B JPY−1.33B JPY−967.3M JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-30.23

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-27.7-36.03-44.37-52.7Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual -50.67, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual -42.49, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 15, 2025: actual -45.79, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 8, 2025: actual -35.43, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual -41.61, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual -33.68, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual -29.73, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual -30.23, estimate —, surprise —, Comparison unavailable.

4598.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,987

-0.34%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,797

+0.57%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,895

0.00%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,210

+0.12%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,858

+0.86%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406.5

+0.82%

Continue in GoAI

Research 4598.T

research.disclaimer